Finding the right balance within the population of dual or triple agonists in development is going to be one of the toughest challenges
New clinical data shows that up to 5% of patients on Zepbound report hair shedding, but the real trigger isnt the medication itself
Three aliquots from each subject were analyzed by NADMED method and another three by targeted LC-MS method
In the trial, nine patients with mild-to-moderate AD were injected with human umbilical cord blood-derived mesenchymal stem cells via stereotactic intraparenchymal surgical injection
"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial." The Lancet , 402(10404), 529-544